調査レポートカテゴリー： MarketsandMarkets, 世界, 医療/バイオ

Bleeding Disorders Treatment Market by Type (Hemophilia A, Hemophilia B, vWD), Drug Class (Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antibrinolytics, Fibrin Sealant) - Global Forecast to 2021

出血障害治療薬の世界市場：血友病A、血友病B、フォン・ウィルブランド病（vWD）

◆タイトル：Bleeding Disorders Treatment Market by Type (Hemophilia A, Hemophilia B, vWD), Drug Class (Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antibrinolytics, Fibrin Sealant) - Global Forecast to 2021
◆商品コード：MAM-PH-4424
◆調査・発行会社：MarketsandMarkets
◆発行日：2016年7月11日
◆ページ数：166
◆レポート形式：PDF / 英語
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆産業分野：製薬
◆販売価格オプション（消費税別）
Single UserUSD5,650 ⇒換算￥621,500見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算￥731,500見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算￥896,500見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※商品の納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。（振込先：三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。（但し、対応範囲は弊社で判断）
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

 【レポートの概要】

当調査レポートでは、出血障害治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、市場シェア分析、疾患別分析、薬品種類別分析、地域別分析、市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。

The global bleeding disorders treatment market is expected to reach USD 15.09 Billion by 2021 from USD 10.33 Billion in 2016 at a CAGR of 7.9% from 2016 to 2021. The major factors driving the market growth include the growing patient population base, R&D activities, and increasing focus on recombinant products by pharmaceutical companies. Emerging markets offer significant growth opportunities for the market. On the other hand, high treatment cost for bleeding disorder treatment products coupled with limited reimbursement is expected to hinder the growth of this market during the forecast period.
The global bleeding disorders treatment market is broadly classified by type and drug class. Based on type, the market is classified as hemophilia A, hemophilia B, vWD, and others. Hemophilia A is the largest segment and is projected to witness a healthy CAGR in forecast period. The growing number of patients suffering from hemophilia A, coupled with increasing awareness, and increasing R&D activities for development of novel products for treating hemophilia A by major pharmaceuticals are key drivers for this market segment.

Based on drug class, the bleeding disorders treatment market is segmented into plasma-derived coagulation factor concentrates, recombinant coagulation factor concentrates, desmopressin, antifibrinolytics, fibrin sealants, and others. The recombinant coagulation factor concentrates segment is expected to witness the highest growth rate during the forecast period. This increasing focus on developing recombinant factors due to their high efficiency in preventing bleeding episodes over plasma-derived products are driving their market demand.

The global bleeding disorders treatment market is dominated by North America, followed by Europe. North America will continue to dominate the global market in the forecast period. The high acceptance for prophylaxis treatment among all age groups in the U.S. is a key market driver in the region.

The key players in the bleeding disorders treatment market are are Shire Plc. (earlier Baxalta) (Ireland), Bayer AG (Germany), Biogen Inc. (U.S.), CSL Behring (U.S.), Novo Nordisk (Denmark), Pfizer Inc. (U.S.), and Grifols SA (Spain).

【レポートの目次】

1 Introduction (Page No. – 9)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Stakeholders
1.6 Assumptions & Limitations

2 Research Methodology (Page No. -16)
2.1 Introduction
2.2 Secondary Data
2.2.1 Key Data from Secondary Sources
2.3 Primary Data
2.3.1 Breakdown of Primaries
2.3.2 Key Data from Primary Sources
2.3.3 Assumptions
2.4 Market Size Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Market Breakdown and Data Triangulation

3 Executive Summary (Page No. – 29)
3.1 Introduction
3.2 Market Dynamics
3.3 Market Estimation

4 Market Dynamics (Page No. – 34)
4.1 Market Drivers
4.1.1 Rising R&D Investment for Development of Hemophilia Products
4.1.2 Increasing Preference for Prophylactic Treatment
4.1.3 Increasing Number of Diagnosed Hemophilia Patients
4.1.4 Increasing Healthcare Expenditure
4.2 Market Restraints
4.2.1 High Cost of Hemophilia Drugs
4.2.2 Insufficient Reimbursement
4.3 Market Opportunities
4.3.1 Local Partnerships in Pharma-emerging Countries
4.3.2 Rising Disposable Income and Improving Healthcare Infrastructure in Developing Nations
4.3.3 Growing Biosimilar Products Market
4.4 Market Threats
4.4.1 High Entry Barriers Created By Local Government in Certain Countries
4.4.2 Low Switch Rate for Hemophilia Products
4.4.3 High Competition from Established Players

5 Global Bleeding Disorders Treatment Market, By Type (Page No. – 46)
5.1 Introduction
5.2 Hemophilia A
5.3 Hemophilia B
5.4 Von Willebrand Disease (vWD)
5.5 Others

6 Global Bleeding Disorders Treatment Market, By Drug Class (Page No. – 58)
6.1 Introduction
6.2 Plasma Derived Coagulation Factor Concentrates Market
6.3 Global Recombinant Coagulation Factor Concentrate Market
6.4 Global Others Bleeding Disorders Treatment Market

7 Global Bleeding Disorders Treatment Market, By Geography (Page No. – 71)
7.1 Introduction
7.2 North America
7.3 Europe
7.4 Asia-Pacific
7.5 Rest of the World (RoW)

8 Competitive Landscape (Page No. – 101)
8.1 Market Share Analysis, By Key Players
8.2 Key Growth Strategies, 2013 -2016
8.3 Key Growth Strategies: New Product Approval/ Launch, 2013 -2016
8.4 Key Growth Strategies: Agreements, 2013 -2016
8.5 Key Growth Strategies: M&A, 2013 -2016
8.6 Key Growth Strategies: Other Strategies, 2013 -2016

9 Company Profiles (Page No. – 108)
9.1 Baxalta (Now Shire)
9.2 Bayer Pharmaceuticals
9.3 Novo Nordisk A/S
9.4 Pfizer Inc.
9.5 Biogen Idec
9.6 CSL Behring
9.7 Grifols
9.8 Octapharma

10 Appendix (Page No. – 158)
10.1 Key Industry Insights
10.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
10.3 Introducing RT: Real Time Market Intelligence
10.4 Related Reports

List of Tables (36 Tables)

Table 1 Pipeline Analysis (Recently Approved)
Table 2 Pipeline Analysis (To Be Approved)
Table 3 Global Bleeding Disorders Treatment Market, By Type, 2014 –2021 (USD Million)
Table 4 Hemophilia A Treatment Market, By Region, 2014 –2021 (USD Million)
Table 5 Hemophilia A Treatment Market, By Disease Management, 2014 –2021 (USD Million)
Table 6 Hemophilia B Treatment Market, By Region, 2014 –2021 (USD Million)
Table 7 Hemophilia B Treatment Market, By Disease Management, 2014 –2021 (USD Million)
Table 8 vWD Treatment Market, By Region, 2014 –2021 (USD Million)
Table 9 Others Treatment Market, By Region, 2014 –2021 (USD Million)
Table 10 Global Hemophilia Treatment Market, By Drug Class, 2014 –2021 (USD Million)
Table 11 Global Plasma Derived Coagulation Factor Concentrate Market, By Class, 2014 –2021 (USD Million)
Table 12 Global Plasma Derived Coagulation Factor Concentrate Market, By Geography, 2014 –2021 (USD Million)
Table 13 Global Recombinant Coagulation Factor Concentrate Market, By Class, 2014 –2021 (USD Million)
Table 14 Global Recombinant Coagulation Factor Concentrate Market, By Geography, 2014 –2021 (USD Million)
Table 15 Other Bleeding Disorders Treatment Market, By Geography, 2014 –2021 (USD Million)
Table 16 Global Market Share, By Region, 2014 -2021 (USD Million)
Table 17 North America: Market Share, By Country, 2014 -2021 (USD Million)
Table 18 North America: Market Share, By Product Type, 2014 -2021 (USD Million)
Table 19 North America: Market Share, By Class, 2014 -2021 (USD Million)
Table 20 North America: Market, By Disease Management, 2014 -2021 (USD Million)
Table 21 Europe: Market Share, By Country,2014 -2021 (USD Million)
Table 22 Europe: Market Share, By Product Type, 2014 -2021 (USD Million)
Table 23 Europe: Market Share, By Class, 2014 -2021 (USD Million)
Table 24 Europe: Market, By Disease Management, 2014 -2021 (USD Million)
Table 25 Asia-Pacific: Market Share, By Country, 2014 -2021 (USD Million)
Table 26 Asia-Pacific Market Share, By Product Type, 2014 -2021 (USD Million)
Table 27 Asia-Pacific: Market Share, By Class, 2014 -2021 (USD Million)
Table 28 Asia-Pacific Market, By Disease Management, 2014 -2021 (USD Million)
Table 29 Row: Market Share, By Country, 2014 -2021 (USD Million)
Table 30 Row: Market Share, By Product Type, 2014 -2021 (USD Million)
Table 31 Row: Market Share, By Class, 2014 -2021 (USD Million)
Table 32 Row: Market, By Disease Management, 2014 -2021 (USD Million)
Table 33 New Product Approval/ Launch, 2013 -2016
Table 34 Agreements, 2013 -2016
Table 35 M&A, 2013 -2016
Table 36 Other Strategies, 2013 -2016

List of Figures (20 Figures)

Fig 1 Global Hemophilia Treatment Market Segmentation
Fig 2 Research Design
Fig 3 Breakdown of Supply-Side Primary Interviews: By Company Type, Designation, Region
Fig 4 Market Size Estimation Diagram
Fig 5 Market Data Triangulation Methodology
Fig 6 Comparative Analysis, Global Market By Type 2015 vs 2021
Fig 7 Comparative Analysis, Global Market By Drug Class 2015 vs 2021
Fig 8 Global Snapshot: Market Scenario, 2015
Fig 9 Impact Analysis: Drivers, Restraints, Opportunities & Challenges
Fig 10 Market: Drivers, Restraints, Opportunities & Challenges
Fig 11 Market Attractiveness, By Type
Fig 12 Market Attractiveness, By Drug Class
Fig 13 Global Market Share, By Region, 2015 (USD Million)
Fig 14 Global Market Scenario, By Geography, 2015
Fig 15 North America: Bleeding Disorders Treatment Market Overview
Fig 16 Europe: Bleeding Disorders Treatment Market Overview
Fig 17 Asia-Pacific: Bleeding Disorders Treatment Market Overview
Fig 18 RoW: Bleeding Disorders Treatment Market Overview
Fig 19 Market Share Analysis, By Key Players, 2015 (%)
Fig 20 Competitive Landscape: Key Developments

【レポートのキーワード】

出血障害、出血障害治療薬、血友病A、血友病B、フォン・ウィルブランド病（vWD）、医薬品、製薬、凝固因子

★調査レポート[出血障害治療薬の世界市場：血友病A、血友病B、フォン・ウィルブランド病（vWD）] ( Bleeding Disorders Treatment Market by Type (Hemophilia A, Hemophilia B, vWD), Drug Class (Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antibrinolytics, Fibrin Sealant) - Global Forecast to 2021 / MAM-PH-4424) 販売に関する免責事項
[出血障害治療薬の世界市場：血友病A、血友病B、フォン・ウィルブランド病（vWD）] ( Bleeding Disorders Treatment Market by Type (Hemophilia A, Hemophilia B, vWD), Drug Class (Plasma Derived Coagulation Factor Concentrates, Recombinant Coagulation Factor Concentrates, Desmopressin, Antibrinolytics, Fibrin Sealant) - Global Forecast to 2021 / MAM-PH-4424) についてEメールでお問い合わせ
◆関連調査資料◆
  • 人工神経（神経機能代替） の世界市場予測（～2022年）
    MAM-MD-5908 / MarketsandMarkets / 2018年1月22日 / MarketsandMarketsが発行した当調査レポートでは、人工神経（神経機能代替） の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、市場シェア分析、種類別分析、技術別分析、用途別分析、地域別分析、人工神経（神経機能代替） の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。...“Neuroprosthetics market projected to grow at a CAGR of 12.4%”The neuroprosthetics market was valued at USD 5.84 billion in 2017 and expected to grow at a CAGR of 12.4% to a USD 10.48 billion market by 2022. Factors driving this market include increasing number of neurological disorders, increasing incidence of hearing loss, increasing prevalence of diabetes, and increasing cases of amputation due to the rising number of accidents & injuries. Availability of alternative treatment, high cost of neuroprosthetics devices, and dearth of trained professionals are the major factors hampering the growth of the market. “Output neural prosthetics segment is accounted...
  • クレアチニン測定の世界市場予測（～2023年）：キット、試薬
    BT-6361 / MarketsandMarkets / 2018年6月11日 / MarketsandMarketsが発行した当調査レポートでは、クレアチニン測定の世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、市場シェア分析、製品（キット、試薬）別分析、テスト種類別分析、サンプル別分析、需要先別分析、クレアチニン測定の世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。...The global creatinine measurement market is expected to reach USD 564.5 Million by 2023 from USD 377.2 Million in 2018, at a CAGR of 8.4%. The growth of this market is mainly driven by increasing incidence of renal disorders, growing incidence of other chronic disorders impacting renal function, rising awareness and adoption of preventive healthcare approaches, implementation of favorable government initiatives to promote renal health, rapid growth in the geriatric population, and increasing number of drug development initiatives. This report segments the creatinine measurement market on the basis of type, type of sample, end user, product, and region. By type,...
  • クレアチニンアッセイキットの世界市場予測（～2022年）：種類、サンプル、地域別分析
    BT-6111 / MarketsandMarkets / 2018年3月21日 / MarketsandMarketsが発行した当調査レポートでは、クレアチニンアッセイキットの世界市場について調査・分析し、エグゼクティブサマリー、市場インサイト、市場概観/市場動向、市場シェア分析、種類別分析、サンプル別分析、地域別分析、クレアチニンアッセイキットの世界市場規模及び予測、市場動向、競争状況、関連企業分析などの情報をお届けいたします。...The global creatinine assay kits market is expected to reach USD 245.4 Million by 2022 from USD 189.6 Million in 2017, at a CAGR of 5.3%. The growth of this market is mainly driven by the increasing incidence of renal disorders, growing incidence of other chronic disorders impacting renal function, growing awareness and adoption of preventive healthcare, favourable government initiatives to promote renal health, rapid growth in the geriatric population, and advancements in biomedical research pertaining to kidney disorders and availability of funding. This report segments the market on the basis of type, type of sample, and region. By type,...

    • ◆H&Iグローバルリサーチ株式会社のお客様（例）◆